関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | tert-Butyl piperazine-1-carboxylate | HCID 143452 | — |
| 反応物 | 3-Bromo-2-methylpyridine | HCID 1201003 | — |
| 試薬 | Sodium t-butoxide | HCID 23676156 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 触媒 | 2-Dicyclohexylphosphino-2',6'-diisopropoxybiphenyl | HCID 16217985 | — |
| 溶媒 | Toluene | HCID 1140 | — |
| 生成物 | Tert-butyl 4-(2-methylpyridin-3-yl)piperazine-1-carboxylate | HCID 68106327 | 82.86% |
反応手順
RuPhos (0.543 g, 1.16 mmol) and palladium (II) acetate (0.131 g, 0.58 mmol) were suspended in toluene (15 mL) at ambient temperature. The resulting mixture was degassed and purged several times and warmed to 50°C under nitrogen for 20 mins. In a separate vessel were mixed 3-bromo-2-methylpyridine (2 g, 11.63 mmol), tert-butyl 4-(2-methylpyridin-3-yl)piperazine-1-carboxylate (2.67 g, 83 %), sodium tertbutoxide (1.676 g, 17.44 mmol) and toluene. The mixture was degassed and purged with nitrogen several times and warmed to 50°C. The catalyst solution was added to the reaction vessel and the resulting mixture degassed and purged wtih nitrogen. The reaction was heated at 100°C overnight. The reaction mixture was allowed to cool to ambient temperature and filtered through GF/F paper, washing with MeOH. The filtrate was concentrated to provide the crude material. This was purified by flash silica chromatography, elution gradient 20 to 70% EtOAc in heptane. Pure fractions were evaporated to dryness to afford tert-butyl 4-(2-methylpyridin-3-yl)piperazine-1-carboxylate (2.67 g, 83 %) as a pale yellow oil.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-4147e405915e4ea7b4607546c536b535 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|